Figures
Abstract
Background
Studies comparing patient survival of hemodialysis (HD) and peritoneal dialysis (PD) have yielded conflicting results and no such study was from South-East Asia. This study aimed to compare the survival outcomes of patients with end-stage renal disease (ESRD) who started dialysis with HD and PD in Singapore.
Methods
Survival data for a maximum of 5 years from a single-center cohort of 871 ESRD patients starting dialysis with HD (n = 641) or PD (n = 230) from 2005–2010 was analyzed using the flexible Royston-Parmar (RP) model. The model was also applied to a subsample of 225 propensity-score-matched patient pairs and subgroups defined by age, diabetes mellitus, and cardiovascular disease.
Results
After adjusting for the effect of socio-demographic and clinical characteristics, the risk of death was higher in patients initiating dialysis with PD than those initiating dialysis with HD (hazard ratio [HR]: 2.08; 95% confidence interval [CI]: 1.67–2.59; p<0.001), although there was no significant difference in mortality between the two modalities in the first 12 months of treatment. Consistently, in the matched subsample, patients starting PD had a higher risk of death than those starting HD (HR: 1.73, 95% CI: 1.30–2.28, p<0.001). Subgroup analysis showed that PD may be similar to or better than HD in survival outcomes among young patients (≤65 years old) without diabetes or cardiovascular disease.
Conclusion
ESRD patients who initiated dialysis with HD experienced better survival outcomes than those who initiated dialysis with PD in Singapore, although survival outcomes may not differ between the two dialysis modalities in young and healthier patients. These findings are potentially confounded by selection bias, as patients were not randomized to the two dialysis modalities in this cohort study.
Citation: Yang F, Khin L-W, Lau T, Chua H-R, Vathsala A, Lee E, et al. (2015) Hemodialysis versus Peritoneal Dialysis: A Comparison of Survival Outcomes in South-East Asian Patients with End-Stage Renal Disease. PLoS ONE 10(10): e0140195. https://doi.org/10.1371/journal.pone.0140195
Editor: Chen-Wei Pan, Medical College of Soochow University, CHINA
Received: August 30, 2015; Accepted: September 22, 2015; Published: October 7, 2015
Copyright: © 2015 Yang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Data Availability: Data is available to all interested researchers upon request. Since the data is clinical data, interested researchers need to submit their research proposals to the Domain Specific Review Board (DSRB) of the National Healthcare Group (NHG) (contact number: +65 64713266) through an employee of the National University Health System (NUHS). Interested researchers may contact the correspondence author for help.
Funding: The authors have no support or funding to report.
Competing interests: The authors have declared that no competing interests exist.
Introduction
End-stage renal disease (ESRD) has become a significant and growing public health problem worldwide. The global average prevalence of ESRD patients on dialysis was 215 per million population [1], and the total number of dialysis patients in 2010 was estimated to be close to two million [2]. Asians have been reported to have higher prevalence rate of ESRD than Caucasians [3]. In Singapore, the prevalence of ESRD was 1436.1 per million population in 2013 and the number of prevalent dialysis patients increased at an average rate of 8% per year from 1999 to 2013 [4]. The dialysis population is projected to increase sharply due to the nation’s aging population and the high prevalence of diabetes [5].
Hemodialysis (HD) and peritoneal dialysis (PD) are the two common forms of dialysis therapy for ESRD. The mortality of ESRD patients who are treated with the two modalities has been investigated in numerous observational studies [6–13]. But which dialysis modality performs better in prolonging life of ESRD patients is not clear. Some studies showed the superior outcomes of HD [6, 7, 9], whereas others demonstrated that PD was equivalent to HD [12, 13], or even better for certain subgroups [8, 10, 11]. Moreover, the vast majority of these comparisons were done in Western countries; in Asia, similar comparative studies were performed in Taiwan and Korea [11–13]. There was no such study from South-East Asia, home to more than 593 million people.
Therefore, in this study, we aimed to compare the survival outcomes of patients starting different dialysis modalities using a multiethnic ESRD patient cohort obtained from a hospital-based registry in Singapore.
Methods
Data
The hospital registry contains data of newly diagnosed ESRD patients in National University Hospital (NUH), Singapore from January 2005 to December 2010. Patients were followed up for a maximum of 5 years (median 3.2 years). Adult patients (≥18-year-old) who began either HD or PD and survived the first 90 days of dialysis were included in this study. The dialysis modality on the 90th day after the first service was considered as the initial modality. Patients were being censored for change of therapy or end of the study period, i.e. August 31, 2013. A total of 871 patients were included, of whom 641 initiated dialysis with HD and 230 with PD. For each patient, the baseline demographic characteristics (age, gender and ethnicity), co-morbid conditions at dialysis initiation (presence of diabetes mellitus [DM], hypertension, cardiovascular disease [CVD], and hyperlipidemia) and laboratory tests, such as left ventricular ejection fraction (LVEF), haemoglobin, serum albumin, phosphate, parathyroid hormone (PTH), alkaline phosphatase (ALP), calcium, urate, urea and estimated glomerular filtration rate (eGFR) were recorded. The postal codes of patients’ home addresses were retrieved from NUH to determine housing type (public residence vs. private residence), as a surrogate measure of socioeconomic status (SES). The information about death (died/alive, date of death and cause of death) was obtained from the National Registry of Disease Office under the approval of Ministry of Home Affairs (MHA), Singapore. Patients’ NRICs were used to match with the databases of MHA to retrieve the all-cause death information.
The Domain Specific Review Board, National Healthcare Group approved this study and waived the informed consent.
Statistical analysis
The patient records data was de-identified and analyzed anonymously. Categorical variables were presented as frequency and percentage for the two groups (HD and PD) separately and compared using either chi-square test or Fisher’s exact test as appropriate. Continuous variables were presented as means ± standard deviation (SD) and compared using t-test. A two-sided p-value of less than 0.05 was considered statistically significant. Age was dichotomized into two groups (young [≤65-year-old]/old [>65-year-old]) in the analysis.
Survival analysis was performed using the flexible Royston-Parmar (RP) parametric model. The RP model is highly flexible alternative to the traditional Cox proportional hazards survival model when the assumption for the Cox model is violated [14]. In initial analysis, the Cox assumption was violated by diabetic status even when the time-varying effects were considered. Royston-Parmar model is able to parametrically model baseline survival functions and it has been shown to greatly improve the ability to accurately predict survival of some patient populations than the Cox model, so some researchers recommended using RP model in prognosticating patient survival [15, 16]. Univariate and multivariate RP survival analysis was performed using step-wise backward selection procedure with p<0.05 as the significance threshold.
The RP models were also estimated using a subsample of propensity score (PS) matched patients. The propensity score was the estimated probability of being treated initially with PD and was calculated using the multivariate logistic regression model. The matching technique was the nearest-neighbor matching within calipers without replacement with 1-to–1 matching (1 PD: 1 HD) and the caliper width was 0.2 of the SD of the logit of the propensity score [17]. This matching approach has been shown to result in the least biased treatment effect estimation among different PS-adjusted methods [18]. After matching, a subsample of 225 patient pairs was formed and then, we tested the balancing of propensity scores for each variable between HD and PD groups. The estimated mean bias in propensity score was 4.9% and 15.1% in the propensity score matched sample and in the raw sample (before matching), respectively.
The same RP model was further applied to subgroups defined by age and diabetes mellitus (young without DM, old without DM, young with DM, and old with DM) and by age and cardiovascular disease (young without CVD, old without CVD, young with CVD, and old with CVD).
The treatment effect on outcome was quantified using the hazard ratio (HR) estimate for PD patients, compared with HD patients, and its associated 95% confidence interval (CI). The values of HR >1 indicate a higher risk for death of PD than HD.
All analyses were performed using STATA (release 11.2; Stata Corp, College Station, TX, USA) statistical software.
Results
Demographic and clinical characteristics are presented in Table 1. Patients initiating dialysis with PD (mean age: 64.3 years) were, on average, 6 years older than those initiating dialysis with HD (mean age: 58.2 years, p<0.001). There was higher proportion of females (57.4% versus 44.2%, p<0.01) and ethnic Chinese (66.1% versus 53.7%, p<0.01) in patients starting PD than those starting HD. At dialysis initiation, DM, hypertension, CVD and hyperlipidemia were more common among the PD patients. In terms of lab tests, patients who started dialysis with PD had higher hemoglobin levels, higher albumin concentrations, lower phosphate levels, and higher eGFR than those who started dialysis with HD.
During the 5-year follow-up period, there were 225 deaths among the patients initiating HD (mortality rate: 7.02%) and 157 deaths among patients initiating PD (mortality rate: 13.7%). Fig 1a shows that the mortality rates for patients starting dialysis with the two modalities were similar in the first 6 months (p = 0.79, log-rank test) but started to differ after 6 months, with the mortality among those treated with PD initially being increasing at a higher rate.
In multivariate flexible Royston-Parmar models, the risk of death was higher in patients starting PD than those starting HD (adjusted HR: 2.08; 95% CI: 1.67–2.59; p<0.001). Other significant predictors of higher risk of death were old age at diagnosis (>65-year-old) and presence of co-morbidity such as DM and CVD at the time of dialysis initiation (Table 2). Fig 2 shows that the adjusted HR of death of patients initiating PD compared to patients initiating HD was significantly higher than 1 during the follow-up period except for the first 12 months of treatment (HR: 1.37; 95% CI: 0.91–2.04; p = 0.13).
In the subsample of 225 propensity score-matched patient pairs, the HR value was 1.73 (95% CI: 1.30–2.28, p<0.001), indicating that the patients initiating dialysis with PD had a higher risk of death than those initiating dialysis with HD. The Kaplan-Meier curves for this matched sample are presented in Fig 1b.
In subgroup analyses, the higher risk of death in patients starting dialysis with PD was observed in old patients without DM, young patients with DM, and old patients with DM during the 5 years of follow-up (Fig 3); however, among 175 young patients without DM (HD: 147, PD: 28), the risk of death did not differ between patients treated initially with PD and those treated initially with HD (adjusted HR: 0.75; 95% CI: 0.24–2.34; p = 0.62). Similar results were observed for subgroups defined by age and CVD (Fig 4). Patients initiating PD had significantly higher risk of death in all groups except for 320 young patients without CVD (HD: 266, PD: 54) (adjusted HR: 0.69; 95% CI: 0.18–2.61; p = 0.59).
Discussion
In this study, we found that the survival outcomes may not differ between patients starting dialysis in the modality of PD and HD during the first year of treatment, but in the long term, the risk of death was significantly higher in patients initiating dialysis with PD. We also found that young (≤65-year-old) patients without diabetes mellitus or cardiovascular disease might benefit more from PD than HD.
Previous studies comparing the mortality of patients on PD and HD have shown varying results [6–9, 11–13, 19–21]. Several studies showed a higher risk of death for patients with PD after the first few years of treatment [6, 7, 9, 11], consistent with our findings, while some previous studies using either large-scale registry data or prospective cohort studies have revealed either better survival on PD in the first period on dialysis [8, 20] or comparable outcomes between the two treatment groups [12, 13, 19, 21].
The differing findings for the relative survival outcomes of the two dialysis modalities in the literature may be explained by several reasons. Firstly, ethnic difference is one possibility [22]. For example, diabetes mellitus is more common in Asian than Caucasian dialysis patients [23, 24]. The prevalence of diabetes mellitus was about 70% in this study and 50% in a Korean study which also found disadvantaged survival outcomes in PD patients [11]. In contrast, the prevalence of diabetes mellitus in Western dialysis patients ranged from 20% to 45% [7, 8, 10, 21, 25]. In addition, it was hypothesized that some Asian patient populations may be more likely to develop diabetes or worsened hyperglycemia during PD treatment because of the glucose-containing dialysis fluid [22].
Secondly, the variation in quality of PD may contribute. Factors such as peritoneal catheters and dialysis fluids used may affect the efficiency and quality of dialysis services [22]. Additionally, PD is monitored by the patient him/herself or a family member, and PD patients go to visit their health care providers infrequently. As a result, infections and complications may be less recognized and timely attended in patients undergoing PD than those undergoing HD in dialysis centers [7].
Thirdly, the differences may be due to selection bias. Nephrologists may tend to recommend PD to patients who have poor prognosis due to weak cardiac function [26], especially those with poor performance status, i.e. assisted activities of daily living or unable to ambulate, which would have precluded them from HD [27]. The better outcomes of HD may also be due to patients’ better economic status. Patients in better economic status may prefer HD because they are less concerned about the loss of productivity due to the treatment [5, 28].
It is not surprising that PD may perform similarly or better in young patients without diabetes mellitus or cardiovascular diseases than HD since consistent results have been reported in many previous studies [7, 11, 13, 29]. For example, the survival outcome of PD and HD was found to be comparable for non-diabetic patients under 55 years in Taiwan [13]. PD may confer a survival advantage to young and healthier patients due to better preservation of residual renal function compared to those undergoing HD [29], and therefore has been suggested to be largely used in the young healthier patients, particularly in countries where the PD utilization rate is low [25]. Moreover, PD has been shown to have advantages in patient satisfaction and quality of life [30, 31]. For example, a previous study of dialysis patients in Singapore [31] showed that patients undergoing PD perceived less burden of kidney disease and dialysis than those undergoing HD. Given the relatively low costs of PD and comparable outcomes, promoting PD in these subgroups is likely to lead to cost-effective care. As the survival advantage of PD in the young healthier patients in our study is not certain, further investigation is warranted.
The limitations of the study should not be overlooked. First, because of the lack of randomized controlled clinical trials, such observational study could only provide information on the effectiveness of dialysis modalities instead of causality between dialysis modality and mortality. Second, despite the efforts made to adjust for socio-demographic and clinical characteristics, there may be unmeasured differences between HD and PD patients, which might lead to excess baseline risk for PD patients. Previous studies have shown that in countries where older and sicker patients are preferentially considered for PD [6], patients treated with PD have a higher risk of death than those treated with HD after adjusting for covariates; while in countries demographic and comorbidity data was comparable in both groups of patients, the disadvantage of PD was not observed. Third, the vascular access type of HD patients was not available. HD vascular access type was reported to be strongly associated with the prognosis of patients [32], and thus comparisons of HD and PD should include such information whenever possible. Last, the data used here was from a single-center study; it may not reflect the dialysis outcomes in other study sites. In view of these drawbacks, caution should be exercised in generalizing the results until further studies could confirm the findings.
In conclusion, there was a survival advantage of patients who initiated HD during 5 years of follow-up. Survival outcomes may not differ between the two dialysis modalities in young and healthier patients and further work is needed to evaluate the possible survival benefit of PD as the first treatment in these patients. These findings are potentially confounded by selection bias as patients were not randomized to the two dialysis modalities in this cohort study.
Acknowledgments
The authors wish to thank colleagues from Division of Nephrology, University Medicine Cluster, National University Health System and the National Registry of Disease Office of Singapore for providing the necessary data for this study.
Author Contributions
Conceived and designed the experiments: FY TL HRC NL. Performed the experiments: FY LWK TL HRC. Analyzed the data: FY LWK. Contributed reagents/materials/analysis tools: FY TL HRC AV EL NL. Wrote the paper: FY LWK TL HRC AV EL NL.
References
- 1. Letsios A. The effect of the expenditure increase in the morbidity and the mortality of patients with end stage renal disease: the USA case. Hippokratia. 2011;15(Suppl 1):16–21. Epub 2011/09/08. pmid:21897753; PubMed Central PMCID: PMC3139673.
- 2. Grassmann A, Gioberge S, Moeller S, Brown G. ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association—European Renal Association. 2005;20(12):2587–93. Epub 2005/10/06. pmid:16204281.
- 3. Hall YN, Hsu CY, Iribarren C, Darbinian J, McCulloch CE, Go AS. The conundrum of increased burden of end-stage renal disease in Asians. Kidney Int. 2005;68(5):2310–6. Epub 2005/10/14. pmid:16221234.
- 4.
National Registry of Diseases Office HPB. Singapore Renal Registry Annual Registry Report 1999–2013 (Preliminary). 2014.
- 5. Tan CC, Chan CM, Ho CK, Wong KS, Lee EJ, Woo KT. Health economics of renal replacement therapy: perspectives from Singapore. Kidney Int Suppl. 2005;(94):S19–22. Epub 2005/03/09. pmid:15752233.
- 6. McDonald SP, Marshall MR, Johnson DW, Polkinghorne KR. Relationship between dialysis modality and mortality. J Am Soc Nephrol. 2009;20(1):155–63. Epub 2008/12/19. pmid:19092128; PubMed Central PMCID: PMC2615722.
- 7. Jaar BG, Coresh J, Plantinga LC, Fink NE, Klag MJ, Levey AS, et al. Comparing the risk for death with peritoneal dialysis and hemodialysis in a national cohort of patients with chronic kidney disease. Ann Intern Med. 2005;143(3):174–83. Epub 2005/08/03. pmid:16061915.
- 8. Heaf JG, Lokkegaard H, Madsen M. Initial survival advantage of peritoneal dialysis relative to haemodialysis. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association—European Renal Association. 2002;17(1):112–7. Epub 2002/01/05. pmid:11773473.
- 9. Termorshuizen F, Korevaar JC, Dekker FW, Van Manen JG, Boeschoten EW, Krediet RT. Hemodialysis and peritoneal dialysis: comparison of adjusted mortality rates according to the duration of dialysis: analysis of The Netherlands Cooperative Study on the Adequacy of Dialysis 2. J Am Soc Nephrol. 2003;14(11):2851–60. Epub 2003/10/22. pmid:14569095.
- 10. Yeates K, Zhu N, Vonesh E, Trpeski L, Blake P, Fenton S. Hemodialysis and peritoneal dialysis are associated with similar outcomes for end-stage renal disease treatment in Canada. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association—European Renal Association. 2012;27(9):3568–75. Epub 2012/03/07. pmid:22391139.
- 11. Kim H, Kim KH, Park K, Kang SW, Yoo TH, Ahn SV, et al. A population-based approach indicates an overall higher patient mortality with peritoneal dialysis compared to hemodialysis in Korea. Kidney Int. 2014;86(5):991–1000. Epub 2014/05/09. pmid:24805104.
- 12. Chang YK, Hsu CC, Hwang SJ, Chen PC, Huang CC, Li TC, et al. A comparative assessment of survival between propensity score-matched patients with peritoneal dialysis and hemodialysis in Taiwan. Medicine. 2012;91(3):144–51. Epub 2012/04/25. pmid:22525667.
- 13. Huang CC, Cheng KF, Wu HDI. Survival analysis: Comparing peritoneal dialysis and hemodialysis in Taiwan. Periton Dialysis Int. 2008;28:S15–S20. ISI:000257889800004.
- 14. Royston P, Parmar MK. Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Statistics in medicine. 2002;21(15):2175–97. Epub 2002/09/05. pmid:12210632.
- 15. Miladinovic B, Kumar A, Mhaskar R, Kim S, Schonwetter R, Djulbegovic B. A flexible alternative to the Cox proportional hazards model for assessing the prognostic accuracy of hospice patient survival. PloS one. 2012;7(10):e47804. Epub 2012/10/20. pmid:23082220; PubMed Central PMCID: PMC3474724.
- 16. Rooney J, Byrne S, Heverin M, Corr B, Elamin M, Staines A, et al. Survival analysis of irish amyotrophic lateral sclerosis patients diagnosed from 1995–2010. PloS one. 2013;8(9):e74733. Epub 2013/10/08. pmid:24098664; PubMed Central PMCID: PMC3786977.
- 17. Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivariate behavioral research. 2011;46(3):399–424. Epub 2011/08/06. pmid:21818162; PubMed Central PMCID: PMC3144483.
- 18. Austin PC, Grootendorst P, Anderson GM. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Statistics in medicine. 2007;26(4):734–53. Epub 2006/05/19. pmid:16708349.
- 19. Weinhandl ED, Foley RN, Gilbertson DT, Arneson TJ, Snyder JJ, Collins AJ. Propensity-matched mortality comparison of incident hemodialysis and peritoneal dialysis patients. J Am Soc Nephrol. 2010;21(3):499–506. Epub 2010/02/06. pmid:20133483; PubMed Central PMCID: PMC2831857.
- 20. van de Luijtgaarden MW, Noordzij M, Stel VS, Ravani P, Jarraya F, Collart F, et al. Effects of comorbid and demographic factors on dialysis modality choice and related patient survival in Europe. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association—European Renal Association. 2011;26(9):2940–7. Epub 2011/02/18. pmid:21325351.
- 21. Liem YS, Wong JB, Hunink MG, de Charro FT, Winkelmayer WC. Comparison of hemodialysis and peritoneal dialysis survival in The Netherlands. Kidney Int. 2007;71(2):153–8. Epub 2006/12/01. pmid:17136031.
- 22. Noordzij M, Jager KJ. Patient survival on dialysis in Korea: a different story? Kidney Int. 2014;86(5):877–80. Epub 2014/11/02. pmid:25360491.
- 23. Frankenfield DL, Ramirez SP, McClellan WM, Frederick PR, Rocco MV. Differences in intermediate outcomes for Asian and non-Asian adult hemodialysis patients in the United States. Kidney Int. 2003;64(2):623–31. Epub 2003/07/09. pmid:12846759.
- 24. Norris KC, Agodoa LY. Unraveling the racial disparities associated with kidney disease. Kidney Int. 2005;68(3):914–24. Epub 2005/08/18. pmid:16105022.
- 25. Mehrotra R, Chiu YW, Kalantar-Zadeh K, Bargman J, Vonesh E. Similar outcomes with hemodialysis and peritoneal dialysis in patients with end-stage renal disease. Arch Intern Med. 2011;171(2):110–8. Epub 2010/09/30. pmid:20876398.
- 26. Shahab I, Khanna R, Nolph KD. Peritoneal dialysis or hemodialysis? A dilemma for the nephrologist. Advances in peritoneal dialysis Conference on Peritoneal Dialysis. 2006;22:180–5. Epub 2006/09/21. pmid:16983966.
- 27. Choo JCJ FM, Ong SY, Krishnasamy T The Singapore General Hospital Peritoneal Dialysis Programme from 2000–2008. Proceedings of Singapore Healthcare. 2012;21(2).
- 28. Pacheco A, Saffie A, Torres R, Tortella C, Llanos C, Vargas D, et al. Cost/Utility study of peritoneal dialysis and hemodialysis in Chile. Peritoneal dialysis international: journal of the International Society for Peritoneal Dialysis. 2007;27(3):359–63. Epub 2007/05/01. pmid:17468491.
- 29. Vonesh EF, Snyder JJ, Foley RN, Collins AJ. The differential impact of risk factors on mortality in hemodialysis and peritoneal dialysis. Kidney Int. 2004;66(6):2389–401. Epub 2004/12/01. pmid:15569331.
- 30. Molsted S, Prescott L, Heaf J, Eidemak I. Assessment and clinical aspects of health-related quality of life in dialysis patients and patients with chronic kidney disease. Nephron Clin Pract. 2007;106(1):c24–33. Epub 2007/04/06. pmid:17409766.
- 31. Yang F, Griva K, Lau T, Vathsala A, Lee E, Ng HJ, et al. Health-related quality of life of Asian patients with end-stage renal disease (ESRD) in Singapore. Quality of life research: an international journal of quality of life aspects of treatment, care and rehabilitation. 2015. Epub 2015/03/25. pmid:25800727.
- 32. Polkinghorne KR, McDonald SP, Atkins RC, Kerr PG. Vascular access and all-cause mortality: a propensity score analysis. J Am Soc Nephrol. 2004;15(2):477–86. Epub 2004/01/30. pmid:14747396.